Bharat Biotech's covaxin faces another hurdle
In a major development Brazil has suspended the clinical studies of Bharat Biotech's Covaxin.
Bharat Biotech on Friday, July 23, 2021 announced cancellation of the MoU it had signed with Precisa Medicamentos and Envixia Pharamaceuticals, to launch the covaxin in the south=american country's market
"In the Coordination of Clinical Research at Anvisa (Copec/GGMED) determined this Friday (23/7) the precautionary suspension of clinical studies of the Covaxin vaccine in Brazil The suspension was carried out as a result of a statement from the Indian company Bharat Biotech Limited International, sent to Anvisa on Friday (23/7), Anvisa, the Brazilian health regulator, said on Friday.
Although the termination is only temporary it needs to be seen how the company displays its efficacy in front of the Brazillian officals.